Literature DB >> 7320634

Metabolism of C-apolipoproteins: kinetics of C-II, C-III1 and C-III2, and VLDL-apolipoprotein B in normal and hyperlipoproteinemic subjects.

M W Huff, N H Fidge, P J Nestel, T Billington, B Watson.   

Abstract

The turnover and metabolism of the individual C apolipoproteins (C-II, C-III1, and C-III2) were studied following the injection of 125I-labeled VLDL into 15 normal and hyperlipoproteinemic subjects. The C apolipoproteins from very low density lipoprotein (VLDL) and high density lipoprotein (HDL) were separated by analytical isoelectric focusing, and subsequent densitometric scanning and radioassay of the stained bands yielded values for specific activity. In 13 of 15 subjects, kinetics of C-II, C-III1, and C-III2 were best described by a one-pool model, whereas two subjects showed biexponential kinetics. The specific activity-time curves for VLDL and HDL were super-imposable, indicating rapid exchange of all C apolipoproteins in hyperlipidemic as well as in normal subjects. In each subject the half-life was similar for C-II, C-III1, and C-III2, which suggests similar synthesis and catabolic mechanisms for each C apolipoprotein. The mass of exchangeable C-II (range 1.0-5.8 mg/kg), C-III1 (2.6-20 mg/kg), and C-III2 (2.0-13 mg/kg) increased with plasma triglyceride concentrations. Values for flux of C-II were 1.0-2.8 mg/d per kg, for C-III1 1.6-5.6 mg/d per kg, and for C-III2 1.2-3.1 mg/d per kg, but they were not related to levels of plasma triglyceride. However the irreversible fractional catabolic rates were inversely related to C apolipoprotein (and triglyceride) mass, suggesting that expansion in C apolipoprotein pool size is related to slower removal, due to the longer residence time of triglyceride-rich VLDL particles in plasma. This was confirmed by similar findings for B apolipoprotein kinetics in VLDL carried out simultaneously.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7320634

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  12 in total

1.  Complexities of plasma apolipoprotein C-III metabolism.

Authors:  Frank M Sacks; Chunyu Zheng; Jeffrey S Cohn
Journal:  J Lipid Res       Date:  2011-03-18       Impact factor: 5.922

2.  Static and turnover kinetic measurement of protein biomarkers involved in triglyceride metabolism including apoB48 and apoA5 by LC/MS/MS.

Authors:  Yi Pan; Haihong Zhou; Ablatt Mahsut; Rory J Rohm; Olga Berejnaia; Olga Price; Ying Chen; Jose Castro-Perez; Michael E Lassman; David McLaren; James Conway; Kristian K Jensen; Tiffany Thomas; Gissette Reyes-Soffer; Henry N Ginsberg; David E Gutstein; Michele Cleary; Stephen F Previs; Thomas P Roddy
Journal:  J Lipid Res       Date:  2014-04-02       Impact factor: 5.922

3.  Increased apolipoprotein C3 drives cardiovascular risk in type 1 diabetes.

Authors:  Jenny E Kanter; Baohai Shao; Farah Kramer; Shelley Barnhart; Masami Shimizu-Albergine; Tomas Vaisar; Mark J Graham; Rosanne M Crooke; Clarence R Manuel; Rebecca A Haeusler; Daniel Mar; Karol Bomsztyk; John E Hokanson; Gregory L Kinney; Janet K Snell-Bergeon; Jay W Heinecke; Karin E Bornfeldt
Journal:  J Clin Invest       Date:  2019-07-11       Impact factor: 14.808

4.  Effects of APOC3 Heterozygous Deficiency on Plasma Lipid and Lipoprotein Metabolism.

Authors:  Gissette Reyes-Soffer; Carol Sztalryd; Richard B Horenstein; Stephen Holleran; Anastasiya Matveyenko; Tiffany Thomas; Renu Nandakumar; Colleen Ngai; Wahida Karmally; Henry N Ginsberg; Rajasekhar Ramakrishnan; Toni I Pollin
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-01       Impact factor: 8.311

5.  Plasma apolipoprotein C-III metabolism in patients with chronic kidney disease.

Authors:  Esther M M Ooi; Doris T Chan; Gerald F Watts; Dick C Chan; Theodore W K Ng; Gursharan K Dogra; Ashley B Irish; P Hugh R Barrett
Journal:  J Lipid Res       Date:  2011-02-06       Impact factor: 5.922

6.  Studies on the in vivo and in vitro distribution of apolipoprotein A-IV in human plasma and lymph.

Authors:  T Ohta; N H Fidge; P J Nestel
Journal:  J Clin Invest       Date:  1985-09       Impact factor: 14.808

7.  Atorvastatin and fenofibrate have comparable effects on VLDL-apolipoprotein C-III kinetics in men with the metabolic syndrome.

Authors:  Dick C Chan; Gerald F Watts; Esther M M Ooi; Juying Ji; Anthony G Johnson; P Hugh R Barrett
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-06-19       Impact factor: 8.311

8.  Plasma apolipoprotein C-III transport in centrally obese men: associations with very low-density lipoprotein apolipoprotein B and high-density lipoprotein apolipoprotein A-I metabolism.

Authors:  Dick C Chan; Minh N Nguyen; Gerald F Watts; P Hugh R Barrett
Journal:  J Clin Endocrinol Metab       Date:  2007-11-13       Impact factor: 5.958

9.  Kinetic studies of the metabolism of rapidly exchangeable apolipoproteins may leave investigators and readers with exchangeable results.

Authors:  Henry N Ginsberg; Rajasekhar Ramakrishnan
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-10       Impact factor: 8.311

10.  ApoC-III Glycoforms Are Differentially Cleared by Hepatic TRL (Triglyceride-Rich Lipoprotein) Receptors.

Authors:  Natalie C Kegulian; Bastian Ramms; Steven Horton; Olgica Trenchevska; Dobrin Nedelkov; Mark J Graham; Richard G Lee; Jeffrey D Esko; Hussein N Yassine; Philip L S M Gordts
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-08-08       Impact factor: 10.514

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.